Tom Daniel, our Chairman, was President, Global Research and Early Development at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen and as Senior Vice President of Discovery Research at Immunex Corporation.
Tom previously served as director at Epizyme, Juno, Sana Therapeutics and VIR Bio. He currently serves as director at Vividion Therapeutics, Gossamer Bio, Aspen Neuroscience, Magenta Therapeutics and Zafgen, Inc. He is a Trustee of Reed College, chairs the Board of Overseers of The Scripps Research Institute, serves on the Board of the Alliance for Lupus Research and on the Biomedical Science Advisory Board of Vanderbilt University Medical Center and is a senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt. Dr. Daniel earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW and completed his residency in Internal Medicine at Massachusetts General Hospital.
Jean George is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma, Calithera Biosciences, Catabasis Pharmaceuticals, Cyteir Therapeutics, Disarm Therapeutics, Flex Pharma, Five Prime Therapeutics, Gemini Therapeutics, Hydra Biosciences, Hypnion (acquired by Eli Lilly), Locana Biotechnologies, Portola Pharmaceuticals, Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapeutics, Verastem and Zeltiq Aesthetics.
Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. She has been in the biopharmaceutical industry for over 20 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division.
Jean joined BancBoston Ventures in 1998 to lead its life sciences investments. There, she led investments in Neurometrix, Ironwood Pharmaceuticals, NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Previously, Jean spent six years working in chemistry and bioresearch and earned an MBA from Simmons College Graduate School of Management.
Previously, Rajul was at Amgen where his last role was Global Development Lead. There he oversaw the development of small molecules and biologics in the oncology and bone health therapeutic areas and was instrumental in advancing the R&D pipeline including regulatory approvals of Xgeva and Prolia.
Rajul completed his BA in chemistry and biochemistry at Rice University, and MD and Internal Medicine internship and residency at UT Southwestern Medical school, where he was a Howard Hughes Fellow. He completed his post-doctoral training in biophysics at Rockefeller University, and fellowship training at MD Anderson Cancer Center, where he was Chief Fellow.
Rajul has active medical licenses in the states of California and Texas. He was previously a volunteer Attending Physician treating underserved patients at UCLA Harbor Medical Center, and is a standing lecturer to graduate students at the UCLA Business of Science Center.